



Providing gold standard disinfection and decontamination technology through the design, development and global deployment of our state-of-the-art SteraMist product line and services

KEY FINANCIAL STATISTICS

\$5.6M
IN TOTAL ORDERS YTD
DRIVEN BY CES SALES*

35%
INCREASE IN YTD
BOOKINGS YOY*

11%
INCREASE IN YTD PRODUCT-
BASED REVENUE YOY*

*at June 30, 2022

INVESTMENT HIGHLIGHTS

CUTTING EDGE TECHNOLOGY

- TOMI BIT is the industry's ONLY low-percentage hydrogen peroxide solution capable of delivering six log kill with a dwell time of seconds
- No compromise to human health or adversely affecting medical and lab equipment

EXPANDING MARKET DEMAND

- Proliferation of MRSA, H1N1, C. Diff, etc. drove initial interest in SteraMist solutions
- Market growing at a CAGR 6.7% over the next five years; expected to reach ~\$28 billion by 2026

GLOBAL CUSTOMER BASE

- Hospitals, healthcare facilities, bio laboratories, state/local institutions, schools, restoration partners, sports organizations, offices, aerospace partners and more
- Rising demand from Asia, Europe & Middle East

REVOLUTIONARY PRODUCT LINE

- The SteraPak is the most mobile SteraMist unit available on the market, placing the innovative SteraMist iHP technology onto the customers back
- Custom Engineered Systems eliminate human error and provide accuracy unmatched by competing solutions

SKILLED MANAGEMENT TEAM

- Visionary CEO Dr. Halden Shane
- Proven success delivering on business, operations and regulatory milestones
- Transformed TOMI's SteraMist Technology to gold standard of disinfections and decontamination technology

SUCCESSFUL BUSINESS MODEL


- Recurring revenue stream from sales of BIT solution
- High margin razor/razor blade model
- Capital efficient business infrastructure

DIVISIONS



UNIQUE NON-CORROSIVE TECHNOLOGY

SteraMist BIT is exclusive of toxic chemicals that are highly corrosive and hazardous, and contains no harmful silver ions



REGISTRATIONS & INTELLECTUAL PROPERTY



32
GRANTED PATENTS

50
PATENTS APPLICATIONS WORLDWIDE

CUTTING EDGE IONIZED HYDROGEN PEROXIDE PROCESS

1. COLD PLASMA




7.8% hydrogen peroxide BIT Solution converts to iHP after passing through a cold plasma arc.

2. DISPERSION




iHP is carried throughout the mist, moving like a gas throughout the treated area.

3. CONTACT



iHP damages pathogenic organisms through oxidation of proteins, carbohydrates, and lipids.

4. DISRUPTION



Cellular disruptions and/or dysfunctions occur and allows for disinfection & decontamination in the targeted area.

MARKET DEMAND


Market is valued at nearly **\$19B** and expanding at a CAGR of **6.7%***

COVID-19 has sharply increased the urgency and need for disinfection and decontamination products


Demand for effective disinfection products has grown consistently since 2014 as a result of the proliferation of **hospital acquired Infections and growing food safety concerns**

ONLY TOMI can deliver disinfection/decontamination that is highly effective (six log kill), fast acting and safe

* Source: Grand View Research



REPRESENTATIVES & DISTRIBUTORS AROUND THE GLOBE



CONTACT INFO

TOMI ENVIRONMENTAL SOLUTIONS, INC. | STERAMIST
8430 Spires Way Suite N
Frederick, MD 21701
TOMIMIST.COM

IMS INVESTOR RELATIONS
John Nesbett/Jen Belodeau
203-972-9200
jnesbett@imsinvestorrelations.com

SAFE HARBOR STATEMENT UNDER THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995

This fact sheet contains forward-looking statements that are based on current expectations, estimates, forecasts and projections of future performance based on management's judgment, beliefs, current trends, and anticipated product performance. These forward-looking statements include, without limitation, statements relating to customer orders for our CES solutions, the advantages of CES solutions and expected growth of sales opportunities. Forward-looking statements involve risks and uncertainties that may cause actual results to differ materially from those contained in the forward-looking statements. These factors include, but are not limited to, the impact of COVID-19 pandemic on our business and customers; our ability to maintain and manage growth and generate sales, our reliance on a single or a few products for a majority of revenues; the general business and economic conditions; and other risks as described in our SEC filings, including our Annual Report on Form 10-K for the fiscal year ended December 31, 2020 filed by us with the SEC and other periodic reports we filed with the SEC. The information provided in this document is based upon the facts and circumstances known at this time. Other unknown or unpredictable factors or underlying assumptions subsequently proving to be incorrect could cause actual results to differ materially from those in the forward-looking statements. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, level of activity, performance, or achievements. You should not place undue reliance on these forward-looking statements. All information provided in this fact sheet is as of today's date, unless otherwise stated, and we undertake no duty to update such information, except as required under applicable law.